Background: Atopic dermatitis is a chronic, recurrent inflammation of the skin, accompanied by severe pruritus. Immune system dysregulation and skin barrier defects are associated with the abnormalities in atopic dermatitis. Myriad pieces of evidence have pointed to the major roles of LL-37 and interleukin-31 (IL31)in atopic dermatitis. The studies on atopic dermatitis are still limited i...

INTRODUCTION This study aimed to assess the frequency of anxiety and depression in a cohort of adult patients with atopic dermatitis (AD) in a tertiary dermatological centre, using the Hospital Anxiety and Depression Scale (HADS). We looked for any correlation between anxiety and depression with skin disease severity. MATERIALS AND METHODS Patients with AD were recruited from the National Ski...

OBJECTIVE To evaluate whether mycophenolate mofetil, a new immunosuppressive agent, is effective for treating moderate-severe atopic dermatitis (AD). DESIGN In an open-label pilot study, mycophenolate mofetil, 1 g, was given orally twice daily for 4 weeks. At week 5, the dosage was reduced to 500 mg twice daily until study end (week 8). Patients were followed up for 20 weeks. SETTING Univer...

J Investig Allergol Clin Immunol 2011; Vol. 21(5): 410-421 © 2011 Esmon Publicidad patients with AD have been found to have increased IgE levels and high-affi nity receptors for IgE [1] it can be assumed that treatment with an anti-IgE antibody may decrease clinical manifestations and disease activity. To test this hypothesis, we conducted a study in patients with a diagnosis of severe AD (SCOR...

BACKGROUND Clinical signs are a core outcome domain for atopic dermatitis (AD) trials. The current lack of standardization of outcome measures in AD trials hampers evidence-based communication. OBJECTIVE We sought to provide evidence-based recommendations for the measurement of clinical signs in AD trials and to inform the Harmonising Outcome Measures for Atopic Dermatitis Initiative. METHO...

BACKGROUND Severe atopic dermatitis (AD) is a recurrent and debilitating disease often requiring systemic immunosuppressive treatment. The efficacy of cyclosporine A (CsA) is well proven but potential side effects are concerning. Several reports point at extracorporeal photopheresis (ECP) as an alternative treatment modality with few and mild side effects. However, no direct comparison between ...

BACKGROUND The efficacy of low-dose medicine (LDM) in childhood mild/moderate eczema is not known. We conducted a double-blind, two-stage, randomized, placebo-controlled clinical trial, lasting 23 months, to address this issue. METHOD Eighty children with chronic mild/moderate eczema were randomly allocated to Group A (placebo) or Group B (treatment group; Galium-Heel®, a low-dose multicompon...

BACKGROUND Some probiotics can ameliorate childhood atopic dermatitis (AD). Prebiotics have also shown some efficacy, although when combined with probiotics as synbiotics, their efficacy may improve. OBJECTIVE We compared the effects of Lactobacillus salivarius and fructo-oligosaccharide (synbiotic) with fructo-oligosaccharide alone (prebiotic) on children with moderate to severe AD. METHOD...